Andrew G. Gianoukakis

Author

Also Known As

A G Gianoukakis, A GIANOUKAKIS, A. G. Gianoukakis, A. Gianoukakis, A.G. Gianoukakis, Andrew G Gianoukakis, Andrew G. Gianoukakis, Andrew George Gianoukakis, Andrew Gianoukakis

108

Publications

4.6K

Citations

H-Index

Concepts

All Affiliations

UCLA Medical Center University of California, Los Angeles Harbor–UCLA Medical Center Massachusetts General Hospital The Ohio State University

About

Andrew G. Gianoukakis is an author at UCLA Medical Center specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	332
2	Health Sciences	3	3	99
3	Cell Biology	2	2	87
4	Engineering	1	1	10
5	Public Health	1	1	50

Andrew G. Gianoukakis

Publications

Citations

H-Index

Page 1

	Year	Citations
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer Martin Schlumberger, Makoto Tahara, Lori J. Wirth, New England Journal of Medicine	2015	2K
Evidence for an Association between Thyroid-Stimulating Hormone and Insulin-Like Growth Factor 1 Receptors: A Tale of Two Antigens Implicated in Graves’ Disease Shanli Tsui, Neil Hoa, Catherine J. Hwang, The Journal of Immunology	2008	358
Increased Generation of Fibrocytes in Thyroid-Associated Ophthalmopathy Raymond S. Douglas, Nikoo F. Afifiyan, Catherine J. Hwang, The Journal of Clinical Endocrinology & Metabolism	2009	209
Aberrant Expression of the Insulin-Like Growth Factor-1 Receptor by T Cells from Patients with Graves’ Disease May Carry Functional Consequences for Disease Pathogenesis Raymond S. Douglas, Andrew G. Gianoukakis, Shweta Kamat, The Journal of Immunology	2007	152
B Cells from Patients with Graves’ Disease Aberrantly Express the IGF-1 Receptor: Implications for Disease Pathogenesis Raymond S. Douglas, Catherine J. Hwang, Nikoo F. Afifiyan, The Journal of Immunology	2008	139
Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer Makoto Tahara, Marcia S. Brose, Lori J. Wirth, European Journal of Cancer	2018	102
Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes Robert I. Haddad, Martin Schlumberger, Lori J. Wirth, Endocrine	2017	101
Prolonged duration of response in lenvatinib responders with thyroid cancer Andrew G. Gianoukakis, Corina E. Dutcus, Nicolas Batty, Endocrine Related Cancer	2018	92
A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Marcia S. Brose, Y. Panaseykin, Bhavana Konda, The Journal of Clinical Endocrinology & Metabolism	2021	81
Monoclonal Pathogenic Antibodies to the Thyroid-Stimulating Hormone Receptor in Graves’ Disease with Potent Thyroid-Stimulating Activity but Differential Blocking Activity Activate Multiple Signaling Pathways Jacqueline A. Gilbert, Andrew G. Gianoukakis, Jane Moorhead, The Journal of Immunology	2006	63

Page 1